ADA Scientific Sessions 2025 Abstract · Jun 13, 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin

By GUO L, SUN Z, ZHANG L et al.

Introduction and Objective: HRS-7535, an oral small molecule GLP-1RA, is under development for T2DM and obesity. The study evaluated its efficacy and safety in T2DM participants (pts) inadequately controlled on metformin. Methods: In this randomized, double-blind, multicenter phase 2 study, 194 pts were randomized (1:1:1:1:1) to receive once-daily doses of HRS-7535 at 15, 30, 60, 90, or placebo (PBO). The 60 and 90 mg doses were targeted dose via titration. Primary endpoint was change from baseline in HbA1c at wk 16. Results: 177 (91.2%) completed 16-wk treatment period. At baseline, mean age was 52.3 yrs, HbA1c was 8.5%, BMI was 26.7 kg/m², body weight (BW) was 73.4 kg, 59.3% were men, and ~80% were taking ≥ 1500 mg/day metformin. At wk 16, the PBO-adjusted least-squares (LS) mean changes in HbA1c for HRS-7535 doses of 15, 30, 60, and 90 mg were -0.94%, -1.34%, -1.57%, and -1.39%, respectively (P<0.001 for all doses vs. PBO). At wk 16, the LS mean percentage change in BW reached -2.63% for the 90 mg group vs. -1.30% for PBO. At wk 16, HRS-7535 showed dose-related reductions in FPG, 2h-PG, and waist circumference. During the 16-wk treatment, 3.2% of HRS-7535 and 30.8% of PBO pts required rescue therapy. TEAEs occurred in 71.8-84.6% of HRS-7535-treated pts vs. 76.8% with PBO. Most TEAEs were gastrointestinal-related (nausea: 7.7-34.2% on HRS-7535 vs. 2.6% on PBO; diarrhea: 5.1-15.4% vs. 0%; vomiting: 2.6-15.8% vs. 0%), and mild to moderate. 9 pts (5.8%) on HRS-7535 had documented hypoglycemia; no Level 2 or higher events were reported. Pts on HRS-7535 showed a trend toward increased serum amylase and lipase levels, with no cases of pancreatitis observed. At wk 16, pts on HRS7535 had a mean pulse rate increase of 0.21-3.18 bpm from baseline. Conclusion: HRS-7535 significantly resulted HbA1c in Chinese pts with T2DM inadequately controlled on metformin and exhibited an acceptable safety profile consistent with other GLP-1RAs. Disclosure: L. Guo: Research Support; Abbott, AstraZeneca, Bayer Pharmaceuticals, Inc, Eli Lilly and Company, Innovent Biologics, Merck & Co., Inc, MSD Life Science Foundation, Novo Nordisk A/S, Sanofi, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Tonghua Dongbao. Z. Sun: None. L. Zhang: None. G. Qin: None. Y. Li: None. Z. Ye: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Xu: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. C. Shu: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. P. Liu: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

doi.org/10.2337/db25-837-pInterventions

AgingResearch.News